Senores Pharmaceuticals IPO subscription started on Friday, December 20, and will close on December 24 as per the schedule. The price band is set at ₹372 to ₹391 per share with a face value of ₹10.
Senores Pharmaceuticals IPO Subscription Status
Senores Pharmaceuticals IPO Subscribed over 14.65x on its second day till 05.00 PM on 23rd December.
- Senores Pharmaceuticals IPO subscription QIB investors portion is 14.65x times, while NII subscribed 25.74x times and RII investors subscribed 40.37x times.
- The company has received bids for 11,93,69,438 shares against 81,46,998 shares on offer on the second day.
- Senores Pharmaceuticals IPO Subscribed over 14.65x on day 2.
- Senores Pharmaceuticals IPO Subscribed over 1.92x on day 1.
About Senores Pharmaceuticals IPO
Senores is one of the great pharmaceuticals focusing on generic medicine. It has also been certified by global food and drug authorities. Nowadays it is committed to providing good quality and manufacturing products to raise new demand in the global healthcare industry. At present, they have a goal of innovation, production, and manufacturing verticals and also have the vision to make more affordable and accessible healthcare, especially for varied types of products. Moreover, they are providing a dynamic strategy, offering them access to products that are good to go. Noticeably, they have the strength of identifying, producing, specialty, underpenetrated, and complex pharmaceutical products, and received the reliability of customers to choose them over and over. It is focused on the US and Canadian markets, simultaneously 43 countries have also felt the presence of them. The company also manufactures critical care injectables and active pharmaceutical ingredients (APIs).
Senores Pharmaceuticals IPO Company Financial Report
The company reported revenue of ₹217.34 crores in 2024 against ₹39.02 crores in 2023. The company reported a loss of ₹32.71 crores in 2024 against a Profit of ₹8.43 crores in 2023.
Senores Pharmaceuticals IPO GMP:
Senores Pharmaceuticals IPO GMP was ₹200 as of Monday, December 23rd. That indicates the IPO is trading at ₹591 with ₹200 premium in the grey market against the issue price of ₹391.
